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Abstract
Background. Responding to rising oncology therapy costs, multiple value frameworks are emerging. However, input
from economists in their design and conceptualization has been limited, and no existing framework has been developed
using preference weightings as legitimate indicators of value. This article outlines use of the nominal group technique to
identify valued treatment attributes (such as treatment inconvenience) and contextual considerations (such as current life
expectancy) to inform the design of a discrete choice experiment to develop a preference weighted value framework for
future decision makers.Methods. Three focus groups were conducted in 2017 with cancer patients, oncology physicians,
and nurses. Using the nominal group technique, participants identified and prioritized cancer therapy treatment and
delivery attributes as well as contextual issues considered when choosing treatment options. Results. Focus groups with
patients (n = 8), physicians (n = 6), and nurses (n = 10) identified 30 treatment attributes and contextual considera-
tions. Therapy health gains was the first priority across all groups. Treatment burden/inconvenience to patients and
their families and quality of evidence were prioritized treatment attributes alongside preferences for resource use and
cost (to patients and society) attributes. The groups also demonstrated that contextual considerations when choosing
treatment varied across the stakeholders. Patients prioritized existence of alternative treatments and oncologist/center
reputation while nurses focused on administration harms, communication, and treatment innovation. The physicians
did not prioritize any contextual issues in their top rankings. Conclusions. The study demonstrates that beyond health
gains, there are treatment attributes and contextual considerations that are highly prioritized across stakeholder groups.
These represent important candidates for inclusion in a discrete choice experiment seeking to provide weighted prefer-
ences for a value framework for oncology treatment that goes beyond health outcomes.
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Rising pharmaceutical spending on oncology therapies
in the United States has demonstrated a need for priority
setting and value assessment (VA) of treatment
options.1,2 These new VA models move away from solely
focusing on clinical benefits to also include wider ‘‘value’’
considerations.3,4 Value-based pricing (VBP) seeks to
achieve a fairer and needs-based provision of care, incor-
porating other requirements deliberated by payers and
stakeholders. In recent years, there has been an emerging
body of literature and frameworks looking to include
VA under VBP.5,6 The Professional Society for
Health Economics and Outcomes Research recently
recommended the need to develop understanding of
what drives payer preferences and incorporate ‘‘novel,’’
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non-health treatment characteristics into future frame-
works and economic evaluations.6 By doing so they
argue that we could achieve the most effective use of
resources and establish a price control measure whereby
drug prices reflect the value they bring to a patient.
Thus, it may be possible to avoid ‘‘suboptimal resource
allocation’’ whereby higher prices for medicines are
established regardless of their benefits.4,7
The United States (US) comprises a multi-payer
health care system where payers (e.g., private insurance
plans or public payers like Medicaid and Medicare)
cover members’ service costs. Private insurance plans
offer a choice of health care ‘‘products’’ (plans) based on
extent of coverage and co-pay arrangements, catering to
more preferences and needs.8 Consumers’ willingness-to-
pay (WTP) and valuation of a health plan often align
with their ability to pay.9 Unlike other multi-payer sys-
tems such as Japan or Germany, in the US no mandate
for creating a set price achieved through negotiation or
unilateral agreement among payers exists. Price negotia-
tion is a key feature of single-payer systems such as the
United Kingdom, which are financed through taxation
and where the government has control of spending.
Forms of health technology assessment (HTA) and
existing mechanisms to determine cost-effectiveness such
as the quality-adjusted life year (QALY) are not
employed universally in US formal decision making.10 In
the United Kingdom, the National Health Service
(NHS) set a £20,000 to £30,000 QALY price limit for
health care services (although alternative assessments of
the appropriate threshold exist11). Thus, understanding
how different payers’ value health care could be used to
inform future VAs is important.
US Value Frameworks
There exists lack of agreement among the suggested VA
frameworks as to which criteria define a treatment’s
value, who should determine ‘‘value,’’ and whether
frameworks should incorporate non-health treatment
considerations (such as the inconvenience to patients and
families), or consider the influence of contextual issues
such as a patient’s current life expectancy prior to treat-
ment. Only the recently amended Institute for Clinical
and Economic Review’s (ICER) value framework has a
formal voting policy roundtable process for including
wider ‘‘benefits and disadvantages’’ of a treatment. Yet
discussions on how these results can be incorporated into
the final VBP calculations and who should determine the
value are still ongoing and do not address the issue of
contextual issues influencing value.12 An ‘‘absence of any
notion of sacrifice when it comes to defining weights for
different attributes within any given framework’’ is not
unique to dealing with the non-health attributes but
affects all treatment attributes being included in value
frameworks.13 Moreover, the context in which ‘‘value’’ is
being determined, preferences of different payer groups,
and potentially non–cost-effective considerations of soci-
ety add further complexity and have the potential to
influence attribute weighting.14 Traditional economic
welfare theory stipulates that those often best placed to
determine the value of a good or service are the consu-
mers who wish to maximize their wellbeing (utility), and
greater utility gain indicates higher value.15,16 Capturing
preferences when there is a lack of current real-world
data through presenting trade-offs between utility gain
from different characteristics (attributes) is dependent on
the contextual framing of the task.
Contingent Valuation Methodology: Discrete
Choice Experiments
When revealed preference (RP) data, showing real-life
actions and consumption of existing market goods are
unavailable, contingent valuation (CV) offers an alterna-
tive approach. CV is a stated preference (SP) approach
presenting hypothetical market scenarios to individuals
who are asked to imagine the loss or gain of a particular
good/service and state their WTP for the gain or willing-
ness to accept (WTA) the loss. These values are inter-
preted as measures of value for the good/service allowing
value estimation of commodities that currently do not
exist within the market.16 One increasing popular SP
methodology used to ‘‘simulate’’ real-world market
options are discrete choice experiments (DCE).17 DCEs
are a preference elicitation approach that presents two or
more alternative options to participants and asks them
choose to between them.18 Due to the method’s theoreti-
cal foundation in behavior theory, DCEs are readily able
to capture human behavior.19 Relatively new to health
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economics, DCEs have a firm methodological back-
ground in transport and environmental economics for cap-
turing and measuring broad well-being utilities with
preferences, thus providing both a mechanism for looking
at potential benefits beyond QALYs to include broader
aspects of well-being and a person’s health consistent with
emerging VA as well as a means for testing how different
contextual information may influence valuations.20,21
DCEs are founded in random utility theory and exam-
ine respondent trade-offs between a good/service’s attri-
butes in order to capture preferences.22-24 This differs
from other SP methods such as visual analogue scales,
ranking/rating, standard gamble, and time-trade-off
commonly used for cost-utility analysis to provide utility
values of a good/service suitable for the construction of
QALYs. Instead, DCEs move away from this traditional
approach of a service/good as objects of utility and
instead assumes utility as being derived from the attri-
butes of the good/service (e.g., a treatment’s cost, length,
and convenience).25 Within economics, an underpinning
assumption is that individuals make utility maximizing
choices revealing ‘‘an underlying (latent) utility func-
tion.’’26(p145),27 Researchers can then capture the impact
of attributes on the benefit derived from a good/service,
estimating utilities and if a payment vehicle attribute
(i.e., cost) is included, WTP or WTA.28
DCEs typically have five stages:
1. Identify appropriate attributes
2. Define and assign attribute levels
3. Generate an experimental design
4. Administer the questionnaire (collect data)
5. Analyze choices
Attribute identification is a crucial stage as this ensures
that the functional form of the utility function for the
good/service can be determined.29 Despite an increase in
DCEs within health economics, the literature on generat-
ing attributes is frequently poorly reported.30-32 In their
examination of attribute development and construction,
Coast and Horrocks,31 Coast and colleagues,30 and Vass
and colleagues33 all refer to the potential for qualitative
work to inform the process. One key advantage of quali-
tative research is that it allows researchers to develop a
deeper understanding as to the contextual factors and
internal decision-making processes that are informing
choices, resulting in more reliable results. The most com-
monly cited qualitative methods for attribute identifica-
tion are focus groups and interviews.33
Maintaining the balance between describing a good/
service adequately using a manageable number of
attributes for the respondent is essential.31,32 Distilling
information into a controllable number of attributes is
key to experimental design development as a DCE that
is too cognitively burdensome could lead to respondents
taking shortcuts or ignoring information.34
Nominal group technique (NGT) has been highlighted
as a means for attribute identification due to its struc-
tured approach and ranking methodology within a face-
to-face focus group setting.35 NGT is a consensus focus
group methodology that differs from standard focus
group methodology using open discussion throughout
and instead is a structured four-stage process that pro-
vides a quick and clear methodology for capturing parti-
cipant responses and getting them to prioritize their
thoughts and perspectives both as a group and individu-
ally.36,37 The key benefit of NGT is that it requires parti-
cipants to prioritize attributes into a manageable list,
thus addressing concerns of cognitively burdensome
DCEs. Furthermore, the methodology has the distinct
advantage over other qualitative consensus methods such
as the ‘‘Delphi methodology’’ as it is quick in ensuring
groups reach a consensus through face-to-face discus-
sions and has a higher response rate success. This is par-
ticularly pertinent for studies with a short project
completion timeframe.38 In contrast, the Delphi metho-
dology can take months to complete with multiple
rounds of surveys being distributed to participants.37
Study Objective
This study sought to inform the development of the first
stage of an oncology VA framework incorporating val-
ued oncology treatment attributes from multiple stake-
holder groups and contextual considerations that could
influence preferences. These will be used to design a
DCE that quantifies preferences and trade-offs and goes
beyond the existing cost-effectiveness approach focused
on health measured using QALYs.
Methods
Nominal Group Technique
The focus groups consisted of a facilitator (CS) and a
session moderator (AB). Sessions took up to 60 minutes.
The four stages of this study’s NGT are outlined
below.37
1. Idea: Following facilitator introduction participants
had 10 minutes to silently reflect and list all cancer
treatments attributes they considered important.
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2. Round Robin: One by one, participants stated attri-
butes while the facilitator wrote them on a board.
Then the moderator supplemented this list with
additional attributes considered in existing value fra-
meworks that had not been stated by the group.
These were generated by a scoping review of VBP
and value frameworks. Groups stated if any should
be added to their collective list.
3. Clarification: Groups discussed each attribute, possi-
ble overlapping and confirmed a definition for each.
4. Ranking: This took two forms. First, silently the
participants independently wrote a ranked attribute
list in order of importance. Second, participants
publicly voted to reach a consensus of the top six
most important attributes. The focus groups were
audio recorded and transcribed. Transcriptions were
anonymized to protect respondent.
Recruitment
Participants were recruited from the Memorial Sloan
Kettering Cancer Centre (MSKCC). Participants were
considered eligible if they were English speaking, 18 to 70
years old, and either previous or existing MSKCC cancer
patients or currently employed by MSKCC as oncology
nurses or physicians. The participants were divided into
groups according to their experiences (patient, nurse, or
physician); thus, each of these three perspectives could be
considered independently. Patients were recruited through
an MSKCC patient support network. The chair of that
network reached out to the membership and invited them
to participate in this study. Nurses and physicians were
recruited through a convenience sample of available clini-
cians working at MSKCC. In particular, physicians were
trainees on rotation and therefore covered a number of
specialties but were younger and less senior than average.
Participants were compensated for their time through a
$50 Amazon Gift Card. Ethical approval was granted by
the University of Glasgow and MSKCC (December 2016).
Data Analysis
Participants’ individual attribute ranking scores were
combined to produce a list of each focus group’s cumula-
tive scores to take forward in the DCE.39 The higher
the score the lower the attribute was prioritized.
Additionally, an attribute list from the public voting
exercise across the three groups was collated. This allows
for the differences between the group consensus and
individual rankings to be examined. If there was overlap
in the attributes names, the attributes were combined.
Qualitative analysis of the transcripts was undertaken
using NVivo software package.40 Due to the structured
format of the focus groups, a deductive analysis
approach was taken.41 That is, the total attribute list
across the groups was used as a predetermined frame-
work for the thematic analysis.41 Key terms used by par-
ticipants to describe attributes were coded according to
the attribute they were describing. This process identified
themes and contextual considerations associated with the
attributes, and also helped recognize interactions or
themes across multiple attributes. Attributes were then
grouped as either contextual considerations or attributes
of the treatment option. Those attributes identified by
the focus groups referring to health-related features of
treatment outcomes were not the focus of the study and
would be presented as part of QALYs within the DCE.
These analyses were used to determine attributes (and
their levels) for inclusion in the DCE and help design the
contextual information presented to DCE participants.
Results
Study Sample
Twenty-four subjects participated in the focus groups
held at MSKCC in February 2017: 8 previous or existing
cancer patients, 10 oncology nurses, and 6 physicians
working within oncology. The sociodemographic charac-
teristics of the participants are shown in Table 1.
The sample was predominantly (75%) female. Both
the patients and nurses groups were had a wide range of
age groups while no physicians over 40 years old were
recruited. Only two participants had prior focus group
experience. Two patients had experience of caring for a
cancer patient. No physicians had personal experiences
of cancer while three nurses did. All participants were in
full-time employment.
Table 1 Participant Sociodemographic Characteristics
Patients
(n = 8),
% (n)
Nurses
(n = 10),
% (n)
Physicians
(n = 6)v
Total,
% (n)
Sex
Male 37% (3) 10% (1) 33% (2) 25% (6)
Female 63% (5) 90% (9) 67% (4) 75% (18)
Age (years)
18–30 12.5% (1) — 17% (1) 8% (2)
31–40 25% (2) 30% (3) 83% (5) 42% (10)
41–50 50% (4) 10% (1) — 21% (5)
51–60 12.5% (1) 40% (4) — 21% (5)
61–70 — 20% (2) — 8% (2)
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Attributes Identified
Thirty attributes were identified (Table 2). Five scoping
review attributes were added. Nurses chose ‘‘any existing
treatments’’ and ‘‘cost to population.’’ Physicians chose
‘‘fairness,’’ ‘‘disease severity,’’ and ‘‘can be used for more
than 1 treatment.’’ Patients added none. As previously
stated, treatment attributes that were health-related and
would be considered part of a QALY were excluded.
Participants often used different terms and phrases to
describe similar concepts which have been grouped
together (Table 2). Table 3 presents the top ranked non-
health and resource use attributes in addition to contex-
tual considerations raised.
Table 2 Attributes and Contextual Considerations Identified Across Focus Groups
Identified Criteria Patients Physicians Nurses
Treatment
attributes
Quality of evidence: Level of evidence/how well
established the treatment is/how does the treatment
work?
Ua U U
Treatment inconvenience/burden: Burden on family and
caregivers/lifestyle modifications/length of time/
timeline of treatment
Ua Ua U
Resource use
and cost attributes
Costs/insurance coverage/financial toxicity/barriers U Ua U
Does it impact others consumption of resources U
Societal costs and consequences/costs to population/
fairness
Ua U
Contextual
considerations
Alternative options/any existing treatments/
psychological benefits hope/patient expectations
Ua U Ua
Disease severity U U
Compassionate staff/communication U Ua
Do I have a voice in the treatment plan? U
Can you offer/recommend any psychosocial support? U
Reputation of oncologist/cancer center Ua
Aspects of prevention U
Will it be helping in any research of future treatment U
Can be used for more than 1 treatment U Ua
aDenotes group voted highest ranked attributes.
Table 3 Top Ranked Contextual Considerations, Non-Health and Resource Use Attributes
Ranking
Focus
Group Activity 1 2 3
Patients Individuala How well established the
treatment is (Scored: 43)
Reputation of the oncologist,
cancer center, group (Scored:
46)
Lifestyle modifications (Scored:
53)
Groupa How well established the
treatment is (6 votes)
Reputation of the oncologist,
cancer center, group (3 votes)
Alternative options (3 votes)
Physicians Individuala Burden and inconvenience to
patients (Scored: 28)
Financial toxicity (Scored: 29) Burden and inconvenience on
family and caregivers (Scored:
40)
Groupa Financial toxicity (5 votes) Burden and inconvenience to
patients (4 votes)
Societal costs and consequences
(2 votes)
Nurses Individuala Communication (Scored: 60) Patient expectations (Scored: 63) Barriers (Scored: 67)
Groupa Communication (6 votes) Innovation (6 votes) Patient expectations (4 votes)
a‘‘Individual’’ refers to the participants’ silent (private) ranking, while ‘‘group’’ denotes the public voting process.
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Definitions by Groups: Treatment Attributes
Quality of Evidence. The patients prioritized availability
of evidence, and stated that their top ranked attribute
across both ranking exercises was ‘‘how well established
the treatment is.’’ This was defined as the amount of data
available to them and linked the attribute with a treat-
ment’s efficacy as the more evidence available, the
clearer their understanding about the true efficacy of a
treatment.
The example of what I would think is at the time I was
treated there was a treatment that was considered better,
but Sloan Kettering didn’t want to use it because it wasn’t
as well-established. Now it’s the standard of care for a long
time. (Patient F)
Similarly, physicians reported that aspects of evidence
quality were important to their decision making, describ-
ing how the ‘‘degree of uncertainty about the outcomes’’
of a treatment would affect their final decision. Nurses
also valued quality of evidence, defining it as a result of
staff working experience of a treatment, describing that
having existing first-hand experience of a treatment’s
effect on patients would provide them with a type of
‘‘data’’ and that the more ‘‘data’’ they had would influ-
ence their choice of a treatment option.
I was looking at that from the provider’s perspective. What
is our experience with it, so we’re more comfortable talking
to the patients about it. (Nurse H)
However, only the patients prioritized evidence quality in
their group voting.
Treatment Inconvenience/Burden. The impact of the
treatment on the lives of the patients and their families
was a commonly prioritized theme across the groups,
despite using different attribute names. For the physi-
cians, what the patients termed ‘‘lifestyle modifications,’’
was referred to as two ‘‘burden and inconvenience’’ attri-
butes; one concerning patients and the other the family
and caretakers. ‘‘Burden and inconvenience on patients’’
resulting from treatments was highlighted as being sepa-
rate from provider burden and from ‘‘burden on family
members and caretakers’’ though very much connected
with one another with one participant describing the rela-
tionship as similar to that of a car ‘‘driver’’ and ‘‘passen-
ger.’’ This ‘‘burden and inconvenience on patients’’ was
further described as encompassing other attributes listed
by the group in NGT stages 1 and 2: ‘‘ease of administra-
tion,’’ ‘‘additional testing,’’ and ‘‘scan interval.’’
The ‘‘burdens’’ of a treatment were prioritized by the
patients and termed ‘‘lifestyle modifications.’’ When try-
ing to define the attribute and why it was key to their
choosing a treatment, patients categorized other attri-
butes such as ‘‘location for treatment’’ and ‘‘disruption
to family’’ as being components of ‘‘lifestyle modifica-
tions.’’ The participants associated need for patients to
make changes to their daily lives with their family as part
of ‘‘lifestyle modifications.’’
And now the frequency of visits can be a barrier, if they have
to come every week and they’re trying to work, you know.
And maybe they don’t finish treatment. (Nurse H)
Resource Use/Cost Attributes. Highly ranked by the
physicians as ‘‘financial toxicity’’ (defined as the financial
cost and burden of the illness on the patient and their
families) and ‘‘societal costs and consequences,’’ costs
and resource use was discussed across groups.42
‘‘Financial toxicity’’ was deemed inclusive of ‘‘out-of-
pocket costs’’ and physicians discussed how these costs
could be termed indirect and direct costs.
Would it be cleaner to do direct and indirect costs, of like,
when you think of financial toxicity the direct costs are the
sum that is on the bill due to the drug, right? And that you
can talk about with the patient, and that’s standard regard-
less of the patient’s circumstances. And then there are the
indirect costs—missing work, someone has to comp you to
pay for parking and go through tolls, but they are actually
two unique things, and one is independent of the patient and
the other one is very patient- and circumstance-dependent.
(Physician D)
Patients further discussed that resources (defined as
‘‘time from staff, time from family, cost of drugs, and
cost of surgery’’) could be categorized as two separate
attributes: ‘‘cost/insurance coverage’’ (costs to the
patient) and ‘‘from the health care system,’’ which was
then redefined as part of the ‘‘does it impact on others
by consuming an inordinate amount of resources’’ con-
sumption of resources’ attribute.
My thought was just that there could be a lot of treatment
plans out there, a lot of things that could be done, some
which consume a lot of resources and I think you might be
offered something that consumes a lot of resources from the
hospital, from the insurance, and just the sense that every
time you consume a resource, there’s a possibility that means
there’s less resources to go for other people. (Patient D)
The issue of societal costs and ‘‘fairness’’ were also con-
sidered within this attribute as well as ‘‘disease rarity.’’
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Physicians agreed that rarity was included yet would not
be discussed with patients.
At least in my mind it’s separated from the things that you
normally talk to about—or talk about a patient [ . . . ] It
has—there is something about valuing a cancer treatment
based on its rarity that is more of a societal issue than some-
thing you talk about with the patient. (Physician I)
Nurses defined ‘‘cost to the patients and family’’ as an
aspect of their highly prioritized ‘‘barriers’’ attribute and
separate from understanding the ‘‘big picture’’ and
‘‘where the dollars are going in health care,’’ which was
termed ‘‘cost to population.’’ This latter attribute was
discussed as a possible cost-effective preventative mea-
sure as early detection could potentially have positive
implications.
It’s almost like not only early detection. It’s, you know—
diet, lifestyle, sleep, stress management, to not get the cancer
in the first place. That would be super effective per cost.
(Nurse J)
Definitions by Groups: Contextual
Considerations
As shown in Table 2, the top ranked contextual consid-
erations across the groups were ‘‘alternative options,’’
‘‘communication,’’ ‘‘patient expectations,’’ ‘‘innovation,’’
and ‘‘reputation of the oncologist, cancer center.’’ All
focus groups stated the importance of knowing if alter-
native treatments were available. The patients listed it as
a top ranked treatment attribute. For patients, knowing
their ‘‘end of the line’’ was essential and for nurses under-
standing if treatments were ‘‘standard of care’’ or ‘‘inves-
tigational’’ (their definition for ‘‘any alternative options’’)
would help their work. This ability to communicate
effectively with patients and manage patients hope and
expectations was discussed by both physicians and nurses
as a key treatment consideration. This sense of responsi-
bility on staff to ensure that the patient had realistic
expectations of the treatment was discussed as being
linked to ‘‘communication,’’ another highly ranked attri-
bute, defined as staff being able to support patients and
families.
I think it’s more widely encompassed by communication,
and that covers length of treatment, compliance, availabil-
ity, you know, so it covers a range of other things that are
all covered in ongoing communication with the patient and
their family. (Nurse D)
The ‘‘innovation’’ of a treatment was a top three nurse
ranked attribute who stated it would be a feature of a
treatment they would consider as ‘‘innovation’’ which
could provide more ‘‘targeted treatment’’ compared to
existing treatments, thus fewer side-effects and better
quality of life. Last, ‘‘reputation of the oncologist/cancer
center’’ was highlighted by patients as key to treatment
choice as this can be tied to an institute. Furthermore,
patients highlighted that center choice could affect
whether any ‘‘offer/provision of psychosocial support’’
was provided and whether they had ‘‘compassionate
staff.’’
Discussion
The findings of this study are twofold, highlighting both
methodological strengths of NGT for DCEs and those
aspects of treatments that are not health outcomes yet
are highly valued by patients, nurses and physicians.
Methodologically, this study has highlighted how
NGT, as a rapid and structured form of qualitative con-
sensus methodology, has been used to show that non-
health attributes and contextual considerations are
important considerations for treatment choice beyond
the health outcome and cost attributes usually included
in a cost-per-QALY VA. Thorough analysis of the tran-
scriptions providing the research team with definitions,
specific terms, and key themes, NGT can aid the design
of more realistic hypothetical choice tasks in a DCE
through its quick and concise ranking approach. This is
invaluable information that can help ensure that the sce-
narios that will be presented to DCE respondents are evi-
dence based in real life and can help result in a survey
with face validity. These identified attributes will now be
taken forward into the design process of a US
population-wide DCE designed to explore whether (and
to what extent) these non-health attributes will be traded
against health. The groups highlighted clear similarities
and differences between the perspectives of the stake-
holders. These differences in rankings will be tested fur-
ther in the initial design processes of the DCE with
different versions used in consultation about the design
and phased piloting of scenarios and the contextual
information with those who have experienced cancer and
who currently work within the oncology field.
The results highlight that for US stakeholders cost to
the individual is a key concern and possible treatment
‘‘barrier.’’ This is unsurprising given the US multi-payer
health care system and existing evidence suggesting that
ability to pay aligns with consumers’ valuations of a
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treatment.9 This demonstrates that in order to elicit pre-
ferences for non-health outcomes of treatment, the treat-
ment costs presented in the DCE will either need to be
disclosed or some statement about costing will be
required to ensure participant engagement.
This study demonstrates that wider contextual issues
are of importance to stakeholders. Attributes such as
communication and reputation of the oncologist, cancer
center/group, and patient expectations are not ‘‘treat-
ment attributes’’ but rather ‘‘context’’ considerations that
will require valuing in the future design of a DCE (the
next stage of this study). The strength of influence these
considerations have on preferences for treatments has
yet to be determined and will be a key research question
taken forward.
Limitations
Guidance on NGT sample size has not been clarified in
the literature and this is not the first study to use a small
number of focus groups.39 The research team were aware
that the restriction of project timeframe to conduct focus
groups may have limited the breadth of attributes men-
tioned, which may have been brought up in subsequent
focus groups. Therefore, the team has consulted a quali-
tative research methodology specialist (now a permanent
member of the research team) to help with the further
development of the DCE. Following her advice to ensure
the validity of the resulting DCE survey, a think-aloud
study with cancer patients has been included in the pilot-
ing stages of the DCE and will be reported in a subse-
quent publication. The research team would encourage
that if it is not possible to conduct focus groups until
reaching saturation in the results then extensive pretest-
ing of the DCE is essential.
Conclusion
The importance of ‘‘treatment burden/inconvenience’’
and ‘‘quality of evidence’’ was evident across the groups
and will be used as the treatment-specific attributes
within the next stage DCE. These two attributes are
already included in some of the US value frameworks
such as the National Comprehensive Cancer Network’s
evidence blocks, which includes ‘‘quality of evidence’’ as
one of the five elements of value, and ICER, who recog-
nizes that wider issues (such as burden on family) should
be considered in their VA framework.12,43 Yet the article
also highlights that for those individuals working with
oncology patients, the role of communication and man-
agement of patient expectations is also a key issue
requiring further investigation. A key aim of the wider
research project is to explore whether individuals would
trade health for an improvement in these non-health out-
comes and thus, informed by this study, the DCE will be
able to help determine the validity of the incorporation
of non-health outcomes into VBP decision making.
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